(MedPage Today) — The FDA approved the kinase inhibitor gedatolisib (Revtorpyk) for treating hormone receptor (HR)-positive/HER2-negative breast cancer in patients whose disease has progressed on endocrine therapy in the metastatic setting.
Approval…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
